Resistant Hypertension, Obesity, Sleep Apnea, and Aldosterone: Theory and Therapy

Hypertension

Volumn 43, Issue 3, 2004, Pages 518-524

  Goodfriend, Theodore L ^a,b,d   Calhoun, David A ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Aldosterone; Fatty acids; Hypertension; Obesity; Renin; Sleep apnea

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; SPIRONOLACTONE;

ADRENAL GLAND; ADRENERGIC SYSTEM; ADULT; ALDOSTERONE BLOOD LEVEL; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DROWSINESS; FATIGUE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERALDOSTERONISM; HYPERLIPIDEMIA; HYPERTENSION; MALE; OBESITY; PLASMA RENIN ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; SNORING; SYMPTOM; UPPER RESPIRATORY TRACT;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; DRUG RESISTANCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, THEORETICAL; OBESITY; SLEEP APNEA SYNDROMES;

EID: 1442338287     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000116223.97436.e5     Document Type: Review

References (59)

1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwaxhuku C, Papademetriou V, Probstfield J, Wright Jr JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North Am settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trail (ALLHAT). J Clin Hypertens. 2002;4:393-404.
2. ALLHAT Investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
3. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
4. Rexrode KM, Manson JE, Hennekens CH. Obesity and cardiovascular disease. Curr Opin Cardiol. 1996;11:490-495.
5. Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16:234-251.
6. Grassi G, Colombo M, Seravelle G, Spazini D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension. 1998;31:64-67.
7. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous system activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96:3423-3429.
8. Masuo K, Mikami H, Ogihara T, Tuck, ML. Familial obesity, sympathetic activation and blood pressure level. Blood Pressure. 2001;10:199-204.
9. Reaven G, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
10. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension. 1997;30:619-623.
11. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, Wiesner GH, Brunner-La Rocca HP, Esler MD. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125-1133.
12. Narkiewicz K, van de Borne PJH. Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation. 1998;98:772-776.
13. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625-633.
14. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obesity Res. 1999;7:355-362.
15. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res. 1998;24:789-796.
16. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304:930-933.
17. Cassis L, Lynch K, Peach M. Location and regulation of rat angiotensinogen messenger RNA. Hypertension. 1988;11:591-596.
18. Hiramatsu K, Yamada T, Ichikawa K, Izumiyama T, Nagata H. Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc. 1981;29:25-30.
19. Quinn SJ, Williams GH. Regulation of aldosterone secretion. Am Rev Physiol. 1988;50:409-426.
20. Ehrhart-Bornstein M, Hinson J, Bornstein S, Scherbaum W, Vinson G. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev. 1998;19:101-143.
21. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects: Effects of saline load. Hypertension. 1994;23:120-124.
22. Goodfriend TL, Ball DL, Gardner HW. An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandins Leukot Essent Fatty Acids. 2002;67:163-167.
23. Roust LR, Jensen MD. Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes. 1993;42:1567-1573.
24. Keaney JF Jr., Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434-439.
25. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Sherbaum WA, Bornstein SR. Human adipocytes secrete mineralocorticoid releasing factors. Proc Nat Acad Sci U S A. 2003;100:14211-14216.
26. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissman P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-896.
27. Calhoun DA, Nishizaka MK, Zaman MA Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004;in press.
28. Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Curr Hypertens Rep. 2001;3:209-215.
29. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova, Niroumand M, Leung RST, Bradley TD. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271-2277.
30. Lavie P, Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant hypertension. Sleep. 2001;24:721-725.
31. Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, Skatrud J. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med. 1997;157:1764-1752.
32. Horner RL, Brooks D, Kozar LF, Tse S, Phillipson EA. Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. J Appl Physiol. 1995;79:151-162.
33. Dimsdale JE, Coy T, Ziegler MG, Ancoli-Israel S, Clausen J. The effect of sleep apnea on plasma and urinary catecholamines. Sleep. 1995;18:377-381.
34. Phillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens. 1999;17:61-66.
35. Fletcher EC, Lesske J, Culman J, Miller CC, Unger T. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension. 1992;20:612-619.
36. Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin BG. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest. 1993;103:1763-1768.
37. Voogel AJ, van Steenwijk, RP, Karemaker JM, van Montfrans GA. Effects of treatment of obstructive sleep apnea on circadian hemodynamics. J Auton Nerv Syst. 1999;77:177-183.
38. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation. 1999;100:2332-2335.
39. Fletcher EC, Bao G, Li R. Renin activity and blood pressure response to chronic episodic hypoxia. Hypertension. 1999;34:309-314.
40. Fletcher EC, Orolinova N, Bader M. Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol. 2002;92:627-633.
41. Møller DS, Lind P, Strung B, Pederson EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens. 2003;16:274-280.
42. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74:761-811.
43. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Eng J Med. 1987;317:350-357.
44. DeFronzo RA, Goldberg M, Agus ZS. The effects of glucose and insulin on renal electrolyte transport. J Clin Invest. 1976;58:83-90.
45. Young WF. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology. 2003;144:2208-2213.
46. Abshagen U, Sporl S, Schoneshofer M, Làge M, Rennekamp H, Oelkers W. Influence of spironolactone on endogenous steroid metabolism in man. Clin Sci Mol Med. 1976;51:307s.
47. Scavo D, Borgia C, Iacobelli A. Aspetti di funzione corticosurrenalica nell obesita. Folia Endocrinol. 1968;21:307-310.
48. Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol. 1986;57:613-618.
49. Wofford MR, Anderson DC, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of α- and β-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14:694-698.
50. Kincaid-Smith P, Fang P, Laver MC. A new look at the treatment of severe hypertension. Clin Sci Mol Med. 1973;45:75s-87s.
51. Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. BMJ. 1980;281:1101-1103.
52. Ouzan J, Pérault C, Lincoff AM, Carré E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15:333-339.
53. Nishizaka MR, Zaman AM, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
54. Rocha R, Stier CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
55. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. 2002;283:H1802-H1810.
56. Struthers AD. Aldosterone: cardiovascular assault. Am Heart J. 2002;144: S2-S7.
57. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999;341:752-755.
58. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
59. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatline M for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med. 2003;384:1309-1321.